VTGN Vistagen Therapeutics, Inc.: institutional ownership and insider trading
56 funds reported holding $4.19M of Vistagen Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net sold $509K, with 8 new positions and 11 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $2.50M and net income of −$67.6M.
VTGN revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.48M, net income −$13.0M, EPS -0.30
- Quarter ended Mar 31, 2026: revenue $464K, net income −$16.3M, EPS -0.37
- Quarter ended Dec 31, 2025: revenue $303K, net income −$18.9M, EPS -0.45
- Quarter ended Sep 30, 2025: revenue $258K, net income −$19.4M, EPS -0.54
Famous investors holding VTGN
- Two Sigma (Two Sigma Investments): $192K, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $165K, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $69.3K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $52.6K, 0.0% of the portfolio
Largest institutional holders of VTGN
- VANGUARD GROUP INC — $1.21M
- Commodore Capital LP — $630K
- VANGUARD CAPITAL MANAGEMENT LLC — $356K
- TWO SIGMA INVESTMENTS, LP — $192K
- ACADIAN ASSET MANAGEMENT LLC — $178K
- RENAISSANCE TECHNOLOGIES LLC — $165K
- Cubist Systematic Strategies, LLC — $156K
- Ikarian Capital, LLC — $117K
- SUSQUEHANNA INTERNATIONAL GROUP, LLP — $106K
- AdvisorShares Investments LLC — $99.1K
5%+ owners
- Commodore Capital LP: 9.9% (Schedule 13G/A, filed Aug 14, 2026)
- Chen Yu: 6.7% (Schedule 13G/A, filed Aug 14, 2026)